Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

62.03USD
15 Jun 2018
Change (% chg)

$0.47 (+0.76%)
Prev Close
$61.56
Open
$61.62
Day's High
$62.10
Day's Low
$61.22
Volume
9,313,264
Avg. Vol
3,637,660
52-wk High
$66.41
52-wk Low
$52.83

Select another date:

Mon, Jun 4 2018

Photo

Merck's Keytruda shows promise in treating advanced melanoma

Merck & Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment. | Video

Merck's Keytruda shows promise in treating advanced melanoma

June 4 Merck & Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment.

UPDATE 1-Merck's Keytruda extends lung cancer survival in 2 trials

CHICAGO, June 3 Merck & Co's immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company's lead in the most lucrative oncology market.

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

REFILE-EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

UPDATE 1-Roche, chasing Merck, notches another lung cancer win

* Detailed trial results due later this year (Adds comment from Roche, details, analyst comments)

Merck's cancer drug Keytruda notches another trial success

Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.

Select another date: